Updates

May 28, 2020May 28, 2020
3 Levels of Care Recommended for Breast Cancer Patients During COVID-19 Pandemic

For breast cancer care during the COVID-19 pandemic, a panel of experts has recommended that patients be divided into one of three categories based ... Read more
May 21, 2020May 21, 2020
Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors ... Read more
May 14, 2020May 14, 2020
Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Seattle Genetics‘ Tukysa, in combination with trastuzumab and Xeloda (capecitabine), for the treatment of patients with metastatic ... Read more
May 7, 2020May 14, 2020
FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

Seattle Genetics’ Tukysa (tucatinib) can now be used in combination with trastuzumab and Xeloda (capecitabine) to treat people with metastatic or inoperable ... Read more
April 30, 2020April 30, 2020
Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan

Enhertu (trastuzumab deruxtecan) has been approved in Japan to treat adults with HER2-positive inoperable or metastatic breast cancer that is resistant to chemotherapy, or ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

June 22, 2018June 22, 2018

Clinical Trial of Tamoxifen-based Gel in Reducing Breast Density Recruiting in US, EU

News

The ability of a gel containing a tamoxifen-byproduct to reduce breast density — associated with an increased risk of breast cancer — is now being evaluated in a recruiting Phase 3 clinical trial. Approximately half of women in ... Read more

3 Levels of Care Recommended for Breast Cancer Patients During COVID-19 Pandemic

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

Concure’s New $2.5M Funding to Boost Patient Access to its Radioactive Seed Treatment

Positive Results Support Early Halt to Phase 3 Trial Testing Sacituzumab Govitecan for TNBC

CytoDyn Seeks Preliminary FDA Meeting on Leronlimab’s Breakthrough Therapy Status

Subscribe to our mailing list

Tumor Suppressor Neurofibromin Interacts with Estrogen Receptor, Revealing Potential Combo Breast Cancer Therapy

Komen Suggests Delaying Routine Mammograms During COVID-19 Outbreak

Herzuma, Biosimilar to Herceptin, Available in US for HER2-positive Breast Cancers

Fewer False-positive Mammograms May Need Human-Computer Mix

Tumor Mutations May Help Predict Patients Best Suited to Pre-surgery Chemotherapy

Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds

Certain Inhaled Anesthetics May Promote Breast Cancer Spread, Mouse Study Suggests

Lesser-known DNA Repair Process May Be Therapeutic Target in Certain Breast Cancers, Study Says

Breast Cancer Cells Precisely Mapped; Study Notes Potential for Individualized Treatment

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

Novel 3D Model Provides Early Insights on Breast Cancer Spread

FDA Approves Nerlynx-Capecitabine Combo for HER2-positive Metastatic Breast Cancer

New Formulation of Roche’s Perjeta-Herceptin Combo for HER2-Positive Breast Cancer Up for Possible FDA Approval

Magseed Approval Extended in Europe for Soft Tissues, Long-Term Implantation

Adding Keytruda to Chemo Slows Worsening in Advanced TNBC with PD-L1 Markers, Trial Finds

Tucatinib Granted FDA Priority Review for Advanced HER2-positive Breast Cancer

Tutu Project’s Pilot Program Helps Breast Cancer Patients Directly With Daily Expenses

AutoNation Donates $720K to Breast Cancer Research Foundation

Study of Treatment Aiming to Prevent Advanced Breast Cancer’s Spread to Bone Doses 1st Patient

Keytruda-Mektovi Combo Deemed Safe in Early Triple Negative Breast Cancer Trial

Researcher Awarded $462K NIH Grant to Study Effects of Endocrine Disruptors on Breast Cancer Risk in Young Women

Susan G. Komen Tissue Bank Teams with LifeOmic to Advance Breast Cancer Research

Ziskin Prize Winners Will Collaborate to Further Immune Checkpoint Inhibitors for Treating Breast Cancer

Artificial Intelligence Could Aid in Breast Cancer Screening, Study Shows

Younger Women Planning Infertility Treatments Should First Receive Mammogram Screening, Study Suggests

Phase 2 Trial of Triple Combo in Treating Advanced Breast Cancer Opening, Zymeworks Says

New Imaging Technique Measures Breast Cancer Metabolism

Leronlimab Combo Shows Promise for Metastatic TNBC in Early Phase 1b/2 Trial Data

New Method Using Sound Waves May Stop Breast Cancer Spread in Lymph Nodes, Mouse Study Shows

CytoDyn Files for FDA Breakthrough Therapy Status for Leronlimab for Metastatic TNBC

Certain Genomic Tests May Soon Be Reimbursable for Breast Cancer Patients in Germany

Pin It on Pinterest